Area of Interest
Stergios Moschos, MD, has a research focus on identifying molecules that are important for melanoma development and progression, identifying mechanisms of action of FDA-approved and investigational agents in melanoma.
For example, he identified that Ubc9, the single SUMO E2 conjugating enzyme is highly expressed in melanoma-infiltrated lymph nodes and that targeting Ubc9 in melanoma cell lines enhances the cytotoxic effect of chemotherapeutic agents. Furthermore, he studied the mechanism of action of high-dose interferon as part of a neoadjuvant trial in patients with stage III melanoma.
Awards and Honors
- National Foundation of Scholarships, 1992
- Hellenic American Society for the Health Sciences, 1992